 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
ImmuCell Announces Financial Results for First Quarter of 2009 PORTLAND, ME – May 5, 2009 - ImmuCell Corporation (NASDAQ Capital Market: ICCC) today announced the results of its operations for the three-month period ended March 31, 2009. For the three-month period ended March 31, 2009, product sales decreased by 10%, or $171,000, to $1,460,000 in comparison to the same period in 2008. "In the current global economic crisis, dairy producers have been hit with significant declines in milk revenue," commented Michael F. Brigham, President and CEO. "We appreciate the volume of business that we have maintained during these times when our customers are being forced to cut costs wherever possible to stay in business." Product development expenses increased by 30%, or $100,000, during the three-month period ended March 31, 2009 in comparison to the same period in 2008 principally reflecting the costs of funding the development of Mast Out®. As of the end of April 2009, approximately 85% of the qualified cases required to reach the targeted study size had been enrolled in the pivotal effectiveness study. The Company reported a loss before income taxes of $(36,000) during the three-month period ended March 31, 2009 in contrast to income before income taxes of $129,000 during the same period in 2008. The net loss was $(35,000) ($(0.01) per diluted share) during the three-month period ended March 31, 2009 in contrast to net income of $78,000 ($0.03 per diluted share) during the same period in 2008. Cash, cash equivalents and short-term investments increased by 2%, or $86,000, to $5,140,000 at March 31, 2009 as compared to $5,054,000 at December 31, 2008. Stockholders' equity increased by 1%, or $98,000, to $9,742,000 at March 31, 2009 as compared to $9,644,000 at December 31, 2008. The Company had 2,971,000 shares of common stock outstanding as of March 31, 2009.
(Unaudited)
Three Months Ended
March 31,
-----------------------
(In thousands, except per share amounts) 2009 2008
---------- -----------
Revenues:
Product Sales $ 1,460 $ 1,631
Other Revenues 1 5
---------- -----------
Total Revenues 1,461 1,636
Cost and expenses:
Product costs 740 814
Product development expenses 432 332
Selling, general and administrative expenses 361 421
---------- -----------
Total costs and expenses 1,533 1,567
---------- -----------
Net operating (loss) income (72) 69
Interest and other income 36 60
---------- -----------
(Loss) income before income taxes (36) 129
Income tax (credit) expense (1) 51
---------- -----------
Net (loss) income $ (35) $ 78
========== ===========
Net (loss) income per common share:
Basic $ (0.01) $ 0.03
Diluted $ (0.01) $ 0.03
Weighted average common shares outstanding:
Basic 2,923 2,892
Diluted 2,923 2,965
(Unaudited)
At At
(In thousands) March 31, December 31,
2009 2008
----------- -----------
Cash, cash equivalents and short-term investments $ 5,140 $ 5,054
Total assets 10,233 10,128
Net working capital 6,398 6,245
Stockholders’ equity $ 9,742 $ 9,644
ImmuCell Corporation is a biotechnology company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at http://www.immucell.com.
Contact: ImmuCell Announces Financial Results for 2008 PORTLAND, ME – February 11, 2009 - ImmuCell Corporation (NASDAQ Capital Market: ICCC) today announced the results of its operations for the quarter and year ended December 31, 2008. For the three-month period ended December 31, 2008, product sales decreased by 16%, or $243,000, to $1,247,000 in comparison to the same period in 2007. For the year ended December 31, 2008, product sales decreased by 3%, or $144,000, to $4,628,000 in comparison to the same period in 2007. "Domestic product sales increased 3% during 2008 (over 2007), while total product sales were down by 3%. As we work to introduce our products (principally First Defense®) to markets outside of the United States, we expect some volatility in those territories. Foreign sales were down by 26% in 2008 (under 2007), but 2008 foreign sales were 18% higher than 2006 foreign sales," commented Michael F. Brigham, President and CEO. "In this very difficult economic environment, we are somewhat satisfied at least to see modest growth in the domestic market while we continue to work to increase our total overall sales." Product development expenses increased by 18%, or $76,000, to $506,000 during the three-month period ended December 31, 2008 in comparison to the same period in 2007. Product development expenses increased by 11%, or $167,000, to $1,746,000 during the year ended December 31, 2008 in comparison to the same period in 2007. During the year ended December 31, 2007, product development expenses included approximately $439,000 in non-cash amortization expense pertaining to a technology asset that was written off during the third quarter of 2007. The loss before income taxes was $(251,000) during the three-month period ended December 31, 2008 in contrast to income before income taxes of $115,000 during the same period in 2007. The net loss was $(40,000) (or $(0.01) per share) during the three-month period ended December 31, 2008 in contrast to net income of $72,000 (or $0.02 per diluted share) during the same period in 2007. The loss before income taxes was $(961,000) during the year ended December 31, 2008 in contrast to income before income taxes of $1,144,000 during the same period in 2007. Our previously disclosed projected loss before income taxes of up to $(750,000) was exceeded principally due to an unexpected decrease in gross margin on product sales. The net loss was $(469,000) (or $(0.16) per share) during the year ended December 31, 2008 in contrast to net income of $662,000 (or $0.22 per diluted share) during the same period in 2007. Technology licensing revenue decreased by $1,248,000 (or 100%), as the result of the product development and marketing agreement that was terminated during the third quarter of 2007. "After nine consecutive years of profitability, our loss before income taxes in 2008 reflects our strategic decision to make a significant and controlled investment in the development of Mast Out®," added Mr. Brigham. "In connection with the development of Mast Out®, we have now enrolled approximately 55% of the qualified cases required to reach our targeted size for the pivotal effectiveness study." Cash, cash equivalents and short-term investments decreased by 7%, or $358,000, to $5,054,000 at December 31, 2008 as compared to $5,412,000 at December 31, 2007. Stockholders' equity decreased by 4%, or $413,000, to $9,644,000 at December 31, 2008 as compared to $10,057,000 at December 31, 2007. The Company had 2,895,000 shares of common stock outstanding as of December 31, 2008.
(Unaudited)
Three Months Twelve Months
Ended Ended
December 31, December 31,
----------------- ----------------
(In thousands, except per share
amounts) 2008 2007 2008 2007
------- -------- ------- --------
Revenues:
Product Sales $ 1,247 $ 1,490 $ 4,628 $ 4,772
Other Revenues 1 13 5 1,297
------- -------- ------- --------
Total Revenues 1,248 1,503 4,633 6,069
Cost and expenses:
Product costs 677 651 2,559 2,269
Product development expenses 506 430 1,746 1,579
Selling, general and administrative
expenses 357 365 1,496 1,349
------- -------- ------- --------
Total costs and expenses 1,540 1,446 5,801 5,197
------- -------- ------- --------
Net operating (loss) income (292) 57 (1,168) 872
Interest and other income 41 58 207 272
------- -------- ------- --------
(Loss) income before income taxes (251) 115 (961) 1,144
Income tax (benefit) expense (211) 43 (492) 482
------- -------- ------- --------
Net (loss) income $ (40) $ 72 $ (469) $ 662
======= ======== ======= ========
Net (loss) income per common share:
Basic $ (0.01) $ 0.02 $ (0.16) $ 0.23
Diluted $ (0.01) $ 0.02 $ (0.16) $ 0.22
======= ======== ======= ========
Weighted average common shares
outstanding:
Basic 2,895 2,892 2,894 2,897
Diluted 2,895 2,990 2,894 3,034
At December 31, At December 31,
(In thousands) 2008 2007
--------------- ---------------
Cash, cash equivalents and short-term
investments $ 5,054 $ 5,412
Total assets 10,128 10,412
Net working capital 6,245 6,710
Stockholders’ equity $ 9,644 $ 10,057
ImmuCell Corporation is a biotechnology company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at http://www.immucell.com. Forward-Looking Statement Disclaimer The foregoing press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 concerning ImmuCell's sales growth. Factors that could cause the Company's future results to differ materially from those described in the forward-looking statements, together with other risk factors, are detailed from time to time in filings we make with the Securities and Exchange Commission, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Forward-looking statements in this press release are based on our current information and expectations. Actual results may differ materially due to various factors, including those risks.
Contact: ImmuCell Initiates Pivotal Trial of Mast Out® PORTLAND, ME – June 5, 2008 - ImmuCell Corporation (NASDAQ Capital Market: ICCC) today announced that it has initiated the pivotal effectiveness field trial of Mast Out®. Planning and preparations for this trial began in July 2007. Completion of the field trial is expected by year-end. Enrollment is targeted at several hundred cows covering multiple locations in the major dairy sheds across the U.S. "Mast Out® has shown strong performance in previous studies," commented Dr. Joseph H. Crabb, vice president and chief scientific officer. "However, this trial is being conducted under an FDA-approved pivotal protocol, and, as such, will be the effectiveness bench mark for this product." Mast Out® is a Nisin-based intramammary infusion product that is being developed as an alternative to traditional antibiotics used in the treatment of mastitis in lactating dairy cows. The safety profile of Nisin and its long history as a food preservative may allow for the sale of Mast Out® in the U.S. without a milk discard requirement, which would be a significant competitive advantage. No other intramammary mastitis treatment product has such a "zero discard" claim. Commercial introduction of Mast Out® in the United States is subject to approval by the U.S. Food and Drug Administration, Center for Veterinary Medicine. ImmuCell Corporation is a biotechnology company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at http://www.immucell.com.
Contact: ImmuCell Announces Cross-License With Anadis PORTLAND, Maine – March 12, 2008 -- ImmuCell Corporation (NASDAQ Capital Market: ICCC) today announced that it had entered into a cross-license of technology with Anadis Limited (ASX: ANX) of Australia. ImmuCell granted Anadis an exclusive, worldwide license to the human and environmental applications of its milk antibody technology. Under this agreement, ImmuCell is not obligated to fund further product development and is entitled to receive a royalty on any sales achieved by Anadis utilizing the technology. In return, ImmuCell was granted a license to the production technology and capabilities of Anadis in Australia. ImmuCell is obligated to pay Anadis a royalty on any sales of First Defense® manufactured in collaboration with Anadis in Australia. Anadis is an Australian-based biotechnology company focused on milk derived polyclonal antibodies and other milk-derived bioactives for human and environmental health applications. ImmuCell Corporation is a biotechnology company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at http://www.immucell.com.
Contact:
Image Credit: Structure of Nisin, courtesy of Dr. Eefjan Breukink of the University of Utrecht, The Netherlands. ¹ Crist, W.L., et al, “Mastitis and Its Control”, University of Kentucky, College of Agriculture, Cooperative Extension Service, ASC-140, p. 2.
|
